0001564590-21-050869.txt : 20211014 0001564590-21-050869.hdr.sgml : 20211014 20211014171041 ACCESSION NUMBER: 0001564590-21-050869 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20211014 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211014 DATE AS OF CHANGE: 20211014 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nurix Therapeutics, Inc. CENTRAL INDEX KEY: 0001549595 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270838048 STATE OF INCORPORATION: DE FISCAL YEAR END: 1130 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39398 FILM NUMBER: 211323955 BUSINESS ADDRESS: STREET 1: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: (415) 660-5320 MAIL ADDRESS: STREET 1: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: Nurix, Inc. DATE OF NAME CHANGE: 20120509 8-K 1 nrix-8k_20211014.htm 8-K nrix-8k_20211014.htm
false 0001549595 0001549595 2021-10-14 2021-10-14

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): October 14, 2021

 

NURIX THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

 

001-39398

 

27-0838048

(State or Other Jurisdiction

of Incorporation or Organization)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

 

 

 

1700 Owens Street, Suite 205

San Francisco, California

 

 

 

94158

(Address of Principal Executive Offices)

 

 

 

(Zip Code)

 

(415) 660-5320

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

NRIX

Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 


 

 

Item 2.02

Results of Operations and Financial Condition.

On October 14, 2021, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended August 31, 2021. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01

Financial Statements and Exhibits.

 

(d)

Exhibits

 

Exhibit No.

 

Exhibit Title or Description

 

 

 

99.1

 

Press Release dated October 14, 2021

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

NURIX THERAPEUTICS, INC.

 

 

 

 

Date: October 14, 2021

 

By:

/s/ Arthur T. Sands

 

 

 

Arthur T. Sands, M.D., Ph.D.

 

 

 

President and Chief Executive Officer

 

3

EX-99.1 2 nrix-ex991_6.htm EX-99.1 nrix-ex991_6.htm

Exhibit 99.1

 

Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer

Expanded Board of Directors with experienced business leaders

Strong financial position with $465.4 million as of August 31, 2021

San Francisco, CA, October 14, 2021 – Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the third quarter ended August 31, 2021 and provided a corporate update.

“With the recent initiation of a Phase 1 trial for our lead E3 ligase inhibitor program NX-1607, we now have two wholly owned drug candidates in clinical development, both potentially addressing significant unmet needs in hematology and oncology,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. “The remainder of 2021 promises to be an exciting time for Nurix as we prepare to deliver on our ambitious goal of initiating Phase 1 trials for two additional wholly owned and internally developed drug candidates.”

Recent Business Highlights

 

Advanced NX-1607 into Phase 1 Clinical Development: Nurix initiated its Phase 1a/1b study to evaluate orally dosed small molecule NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor at clinical sites in the United Kingdom. The multicenter, open-label Phase 1 dose escalation and expansion trial will evaluate the safety and tolerability of NX-1607 in adults with a variety of oncology indications.

 

Expanded the Board of Directors with Experienced Business Leaders: Nurix announced the appointments of Judith A. Reinsdorf and Paul M. Silva to its board of directors, effective October 1, 2021. Ms. Reinsdorf is the former executive vice president and general counsel of Johnson Controls International, and Mr. Silva is the former senior vice president, chief accounting officer at Vertex Pharmaceuticals Incorporated. Nurix previously announced the appointment of Clay Siegall, Ph.D., to its board, effective May 28, 2021. Dr. Siegall is the co-founder of Seagen Inc. (formerly Seattle Genetics, Inc.) and serves as its president, chief executive officer and chairman of the board.

Upcoming Program Highlights*

 

NX-2127: Nurix’s lead drug candidate from its protein degradation portfolio, NX-2127, is an orally bioavailable degrader of BTK with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies. Nurix is conducting its Phase 1 clinical trial of NX-2127 at multiple clinical sites. Initial pharmacokinetic (PK) and pharmacodynamic (PD) data from the dose escalation portion of the trial is anticipated by year-end 2021. Additional information on the clinical trial can be accessed at ClinicalTrials.gov (NCT04830137).

 

NX-1607: Nurix’s lead drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally bioavailable inhibitor of CBL-B for immuno-oncology indications. Nurix recently initiated the dose escalation portion of its ongoing Phase 1 trial.

 

NX-5948: Nurix’s second drug candidate from its protein degradation portfolio, NX-5948, is an orally bioavailable BTK degrader designed without IMiD activity for certain B-cell malignancies and autoimmune diseases. Nurix anticipates initiating a Phase 1 trial for NX-5948 in patients with hematologic malignancies in the second half of 2021 and is planning for the potential expansion of indications into selected autoimmune diseases in 2022.

 

DeTIL-0255: Nurix’s lead candidate in its cellular therapy portfolio, DeTIL-0255, is a drug-enhanced adoptive cellular therapy. Nurix anticipates initiating a Phase 1 trial for DeTIL-0255 in the second half of 2021.

* Expected timing of events throughout the press release are based on calendar year quarters.

Fiscal Third Quarter 2021 Financial Highlights

Collaboration revenue for the three months ended August 31, 2021 was $10.3 million compared to $4.1 million for the three months ended August 31, 2020. The increase was due to the continued scale up of internal resources and external spending for our collaborations with Sanofi and Gilead as compared to the prior period, resulting in a higher percentage of completion in the current period. The increase was also due to partial revenue recognized during the three months ended August 31, 2021 for the achievement of certain preclinical milestones under our collaborations with Gilead and Sanofi.

 


Research and development expenses for the three months ended August 31, 2021 were $30.9 million compared to $18.9 million for the three months ended August 31, 2020. The increase was primarily related to an increase of $4.1 million in compensation and related personnel costs attributable to an increase in headcount. There was also an increase of $1.6 million in non-cash stock-based compensation expense. In addition, there was an increase of $1.9 million in supplies and contract research and an increase of $1.8 million in preclinical activities and contract manufacturing attributable to increases in our preclinical development activities and drug discovery research and an increase of $1.5 million in clinical costs due to ongoing clinical trial startup and patient enrollment.

General and administrative expenses for the three months ended August 31, 2021 were $8.3 million compared to $4.3 million for the three months ended August 31, 2020. The increase was primarily related to an increase of $1.2 million in compensation related expenses attributable to a higher headcount and an increase of $1.6 million in non-cash stock-based compensation expense. There was also an increase of $0.9 million in consultant and other professional service expenses primarily related to becoming a public company.

Net loss for the three months ended August 31, 2021 was $28.8 million, or ($0.65) per share, compared to a net loss of $18.5 million for the three months ended August 31, 2020, or ($1.09) per share.

Cash, Cash Equivalents and Investments: As of August 31, 2021, Nurix had cash, cash equivalents and investments of $465.4 million compared to $372.0 million as of November 30, 2020. The increase was primarily attributable to the net proceeds of $150.2 million from Nurix’s follow-on offering in March 2021.

About Nurix Therapeutics, Inc.

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.

Forward Looking Statement

This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this press release, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to Nurix, may identify forward-looking statements. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective drug candidates; the planned timing and conduct of our clinical trial programs for our drug candidates, preclinical activities, research and development costs, current and prospective collaborations; the potential advantages of our DELigase™ platform and drug candidates; the extent to which our scientific approach and DELigase™ platform may potentially address a broad range of diseases; the estimated size of the market for our drug candidates; and the timing and success of our development and commercialization of our anticipated drug candidates. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions regarding the future of Nurix’s business, future plans and strategies, its development plans, its preclinical results, future conditions and other factors Nurix believes are appropriate in the circumstances. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) risks and uncertainties related to Nurix’s ability to advance its drug candidates, obtain regulatory approval of and ultimately commercialize its drug candidates; (ii) the timing and results of preclinical and clinical trials; (iii) Nurix’s ability to fund development activities and achieve development goals; (iv) the impact of the COVID-19 pandemic on Nurix’s business, clinical trials, financial condition, liquidity and results of operations; (v) Nurix’s ability to protect intellectual property and (vi) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 16, 2021, Nurix’s Quarterly Report on Form 10-Q filed with the SEC on October 14, 2021, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.


Contacts:

 

Investors:

Media:

Jason Kantor, Ph.D.

Elizabeth Wolffe, Ph.D.

Nurix Therapeutics, Inc.

Wheelhouse Life Science Advisors

jkantor@nurixtx.com

lwolffe@wheelhouselsa.com

 


 

Nurix Therapeutics, Inc.

Condensed consolidated statements of operations

(in thousands, except share and per share amounts)
(unaudited)

 

 

 

Three Months Ended August 31,

 

 

Nine Months Ended August 31,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Collaboration revenue

 

$

10,252

 

 

$

4,085

 

 

$

22,354

 

 

$

11,131

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

30,906

 

 

 

18,939

 

 

 

79,903

 

 

 

46,049

 

General and administrative

 

 

8,343

 

 

 

4,338

 

 

 

22,384

 

 

 

10,057

 

Total operating expenses

 

 

39,249

 

 

 

23,277

 

 

 

102,287

 

 

 

56,106

 

Loss from operations

 

 

(28,997

)

 

 

(19,192

)

 

 

(79,933

)

 

 

(44,975

)

Interest and other income, net

 

 

39

 

 

 

675

 

 

 

528

 

 

 

1,071

 

Loss before income taxes

 

 

(28,958

)

 

 

(18,517

)

 

 

(79,405

)

 

 

(43,904

)

Provision (benefit) for income taxes

 

 

(123

)

 

 

 

 

 

87

 

 

 

(20,576

)

Net loss

 

$

(28,835

)

 

$

(18,517

)

 

$

(79,492

)

 

$

(23,328

)

Net loss per share attributable to common

   stockholders, basic and diluted

 

$

(0.65

)

 

$

(1.09

)

 

$

(1.88

)

 

$

(2.90

)

Weighted-average number of shares outstanding,

   basic and diluted

 

 

44,374,389

 

 

 

16,937,934

 

 

 

42,344,420

 

 

 

8,052,905

 


 

Nurix Therapeutics, Inc.
Condensed consolidated balance sheets
(in thousands)
(unaudited)

 

 

 

August 31

 

 

November 30,

 

 

 

2021

 

 

2020

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

147,440

 

 

$

119,356

 

Short-term investments

 

 

196,458

 

 

 

161,792

 

Contract assets

 

 

5,000

 

 

 

7,500

 

Income tax receivable

 

 

204

 

 

 

3,846

 

Prepaid expenses and other current assets

 

 

9,343

 

 

 

5,940

 

Total current assets

 

 

358,445

 

 

 

298,434

 

Long-term investments

 

 

121,480

 

 

 

90,890

 

Property and equipment, net

 

 

9,569

 

 

 

6,672

 

Restricted cash

 

 

286

 

 

 

170

 

Other assets

 

 

3,294

 

 

 

177

 

Total assets

 

$

493,074

 

 

$

396,343

 

Liabilities and stockholders' equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

3,861

 

 

$

3,412

 

Accrued and other current liabilities

 

 

11,569

 

 

 

8,328

 

Deferred revenue, current

 

 

35,250

 

 

 

32,799

 

Total current liabilities

 

 

50,680

 

 

 

44,539

 

Deferred revenue, net of current portion

 

 

66,381

 

 

 

60,685

 

Other long-term liabilities

 

 

796

 

 

 

850

 

Total liabilities

 

 

117,857

 

 

 

106,074

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Common stock

 

 

45

 

 

 

39

 

Additional paid-in-capital

 

 

558,421

 

 

 

393,841

 

Accumulated other comprehensive income (loss)

 

 

(59

)

 

 

87

 

Accumulated deficit

 

 

(183,190

)

 

 

(103,698

)

Total stockholders’ equity

 

 

375,217

 

 

 

290,269

 

Total liabilities and stockholders’ equity

 

$

493,074

 

 

$

396,343

 

 

EX-101.SCH 3 nrix-20211014.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 nrix-20211014_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Tax Identification Number Entity Tax Identification Number Entity Central Index Key Entity File Number Entity File Number Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province City Area Code City Area Code Entity Address, Postal Zip Code Entity Address Postal Zip Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Trading Symbol Trading Symbol Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name EX-101.PRE 5 nrix-20211014_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 nrix-8k_20211014_htm.xml IDEA: XBRL DOCUMENT 0001549595 2021-10-14 2021-10-14 false 0001549595 8-K 2021-10-14 NURIX THERAPEUTICS, INC. DE 001-39398 27-0838048 1700 Owens Street Suite 205 San Francisco CA 94158 415 660-5320 false false false false Common Stock, $0.001 par value per share NRIX NASDAQ true false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Oct. 14, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 14, 2021
Entity Registrant Name NURIX THERAPEUTICS, INC.
Entity Tax Identification Number 27-0838048
Entity Central Index Key 0001549595
Entity File Number 001-39398
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1700 Owens Street
Entity Address, Address Line Two Suite 205
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
City Area Code 415
Entity Address, Postal Zip Code 94158
Local Phone Number 660-5320
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Trading Symbol NRIX
Title of 12(b) Security Common Stock, $0.001 par value per share
Security Exchange Name NASDAQ
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:GH_ 0 / ( \ !X;"]W;W)K8F]O:RYX;6R-49:EL@9OTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^ MR[S!H)>+D6M#V743&4K&& 3L@!W".?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH M7*M4Q_-+)+S$P,9M2XK.%7HR#'9 C.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92X MW^CYC6@\@2P/73>TFH=>Y!L/?P&HT=S8\?M_P! M4$L#!!0 ( $^)3E,D'INBK0 /@! : >&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% M 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF& M!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " !/B4Y399!YDAD! #/ P $P %M#;VYT96YT7U1Y M<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[: M2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)* MM9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK M>MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ M!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO. M\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( $^)3E,'04UB@0 +$ M 0 " 0 !D;V-0&UL4$L! A0#% M @ 3XE.4Z:>],'N *P( !$ ( !KP &1O8U!R;W!S M+V-O&UL4$L! A0#% @ 3XE.4YE&PO=V]R:W-H965T&UL4$L! A0#% @ 3XE.4Y^@&_"Q @ X@P T M ( !O0P 'AL+W-T>6QE&PO=V]R:V)O M;VLN>&UL4$L! A0#% @ 3XE.4R0>FZ*M ^ $ !H M ( ![A$ 'AL+U]R96QS+W=O9(9 0 SP, !, ( !TQ( %M#;VYT96YT7U1Y ><&5S72YX;6Q02P4& D "0 ^ @ '10 end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports nrix-8k_20211014.htm nrix-20211014.xsd nrix-20211014_lab.xml nrix-20211014_pre.xml nrix-ex991_6.htm http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nrix-8k_20211014.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "nrix-8k_20211014.htm" ] }, "labelLink": { "local": [ "nrix-20211014_lab.xml" ] }, "presentationLink": { "local": [ "nrix-20211014_pre.xml" ] }, "schema": { "local": [ "nrix-20211014.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "nrix", "nsuri": "http://www.nurixtx.com/20211014", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "nrix-8k_20211014.htm", "contextRef": "C_0001549595_20211014_20211014", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "nrix-8k_20211014.htm", "contextRef": "C_0001549595_20211014_20211014", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.nurixtx.com/20211014/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001564590-21-050869-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-050869-xbrl.zip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end